Phathom Pharmaceuticals, Inc.
PHAT scores 24.0 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Net penalties of -12.3 points significantly impact the ranking. Without these adjustments, PHAT would rank considerably higher.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| PHAT | 24.0 | N/A | 8001.5% | -186.5% | $1.1B |
| INCY | 89.6 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 85.6 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 82.1 | 13.7 | 23.5% | 37.6% | $3.0B |
| VRTX | 78.0 | 32.1 | 8.9% | 32.9% | $121.8B |
| ASND | 75.8 | 16.6 | 98.0% | -31.7% | $13.8B |
| NBIX | 74.8 | 26.5 | 21.4% | 16.7% | $13.1B |
| AMGN | 73.9 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.5 | 35.1 | 78.6% | 38.0% | $47.4B |
| HOLX | 73.3 | 31.1 | 1.7% | 13.8% | $16.8B |
| REGN | 72.4 | 19.4 | 1.0% | 31.4% | $80.2B |
| ISRG | 72.2 | 61.7 | 20.5% | 28.4% | $180.9B |
| EXEL | 71.6 | 15.1 | 7.0% | 33.7% | $11.9B |
| ALKS | 71.5 | 16.5 | -6.4% | 23.9% | $5.0B |
| KRYS | 71.0 | 41.4 | 473.0% | 30.7% | $7.9B |
| HALO | 70.3 | 16.8 | 22.4% | 43.7% | $8.2B |
| Sector Average | 37.0 | 41.9 | 161.5% | -3292.7% | โ |
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $50M | $40M | $29M | $30M |
| Gross Profit | $43M | $34M | $25M | $26M |
| Operating Income | $-15M | $-60M | $-79M | $-59M |
| Net Income | $-30M | $-76M | $-94M | $-74M |
| EPS (Diluted) | $-0.41 | $-1.05 | $-1.31 | $-1.05 |
| Gross Margin | 87.5% | 87.2% | 86.9% | 87.1% |
| Operating Margin | -30.8% | -151.7% | -276.5% | -200.3% |
| Net Margin | -60.5% | -191.9% | -330.7% | -251.0% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $17.42 | $50.78 | 97.9% | Wide |
| 2022 | $6.10 | $20.30 | 107.6% | Wide |
| 2023 | $5.84 | $17.02 | 97.8% | Wide |
| 2024 | $6.07 | $19.71 | 105.8% | Wide |
| 2025 | $2.21 | $18.31 | 156.9% | Wide |
Growth estimates have been dampened based on technical and fundamental signals. This is a post-hoc adjustment to prevent overly optimistic projections for stocks showing declining momentum or deteriorating fundamentals.
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.